ReviewInternational journal of pharmaceutics: X2025
Construction and applications of exosome-microneedle integrated systems.
Review in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Research advances in microneedle-exosome delivery systems for the treatment of multisystem diseases.Regenerative therapy · 2026Review
- Review
- Exosome-Based Therapeutics in Dermatology and Beyond: A Narrative Review.Biomedicines · 2026Review
- Engineered MSC-Exosomes Delivering miRNAs for Respiratory Disease Diagnostics and Therapy: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- Recent advances in dissolving microneedles for breast cancer immunotherapy: local delivery and tumor microenvironment remodeling.Frontiers in immunology · 2026Review
- Traditional Chinese medicine derived exosome-like nanovesicles in wound repair and skin regeneration.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rapid advancement of drug delivery technologies, microneedles (MNs) have emerged as a novel transdermal delivery platform due to their ease of administration, minimally invasive nature, and high efficiency. MNs have demonstrated broad applicability for delivering diverse therapeutic agents, including small molecules, nucleic acids, peptides, and proteins. Exosomes (Exos), a class of extracellular vesicles with unique biological functions and significant clinical potential, have attracted increasing attention in recent years. However, their widespread application is limited by issues such as poor stability, low delivery efficiency, and potential safety and immune risks. The integration of Exos with MNs (Exos-MNs) systems offers a promising strategy to address these challenges. This review provides a comprehensive overview of recent advances in Exos-MNs delivery systems, including the technological advances of MNs, biological characteristics and engineering strategy of Exos, and the construction strategies of Exos-MNs. Additionally, we highlight recent developments in the application of Exos-MNs systems and discuss future perspectives and challenges for their clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.